Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
Drug formulation: Easing the toll of caregiving Switching from oral to long-acting injectable antipsychotic medication improves overall caregiver burden. The physical, emotional and financial toll of providing care for patients with schizophrenia is often underestimated. Poor adherence to convention...
Main Authors: | Srihari Gopal, Haiyan Xu, Kelly McQuarrie, Adam Savitz, Isaac Nuamah, Kimberly Woodruff, Maju Mathews |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2017-07-01
|
Series: | npj Schizophrenia |
Online Access: | https://doi.org/10.1038/s41537-017-0025-5 |
Similar Items
-
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
by: Mathews M, et al.
Published: (2019-05-01) -
Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate
by: Rebekka Lencer, et al.
Published: (2021-05-01) -
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
by: Mathews M, et al.
Published: (2018-10-01) -
Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
by: Nash AI, et al.
Published: (2019-03-01) -
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
by: Coppola Danielle, et al.
Published: (2012-03-01)